Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Garcia, Marta ^a,b   Velez, Roberto ^a,b   Romagosa, Cleofé ^a,b   Majem, Blanca ^a,b   Pedrola, Núria ^a,b   Olivan, Mireia ^a   Rigau, Marina ^a,b   Guiu, Marc ^c   Gomis, Roger R ^c,d   Morote, Juan ^a,b   Reventós, Jaume ^a,b,e   Doll, Andreas ^a,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Bone metastases; Celecoxib; Cyclooxygenase 2; Prostate cancer

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; TIBIA; ANIMAL; BONE METASTASES; BONE TUMOR; CYCLOOXYGENASE-2; DISEASE COURSE; METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR;

BONE METASTASES; CELECOXIB; CYCLOOXYGENASE-2; PROSTATE CANCER;

ANIMALS; BONE NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; MALE; MICE, NUDE; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84902316197     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12503     Document Type: Article

References (100)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6 (Pubitemid 17234155)
2. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89: 2031-7 (Pubitemid 38030899)
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12 (20 Pt 2): 6243s-9s
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
5. Roodman GD. Mechanisms of bone metastasis.N Engl J Med 2004; 350: 1655-64
6. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76 (Pubitemid 32452017)
7. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8 (Pubitemid 37328849)
8. Lieberman R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev 2002; 21: 297-309 (Pubitemid 36071917)
9. Dannenberg AJ, Altorki NK, Boyle JO et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-51 (Pubitemid 33586867)
10. Mendes RT, Stanczyk CP, Sordi R, Otuki MF, Santos FA, Fernandes D. Selective inhibition of cyclooxygenase-2: risks and benefits. Rev Bras Reumatol 2012; 52: 774-82
11. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45-82 (Pubitemid 29231727)
12. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58 (2 Suppl. 1): 127-31 (Pubitemid 32743428)
13. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 135-8 (Pubitemid 30064985)
14. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer: correlation with prognostic variables and outcome. Appl Immunohistochem Mol Morphol 2007; 15: 255-9 (Pubitemid 47329915)
15. Gupta S, Adhami VM, Subbarayan M et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334-43 (Pubitemid 38581441)
16. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005; 11: 3250-6 (Pubitemid 40627872)
17. Cohen BL, Gomez P, Omori Y et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006; 119: 1082-7 (Pubitemid 44116917)
18. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16 (Pubitemid 30066236)
19. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29: 23-8
20. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21 (2B): 1291-4
21. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-8 (Pubitemid 30004877)
22. Yoshimura R, Sano H, Masuda C et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-96 (Pubitemid 30640105)
23. Madaan S, Abel PD, Chaudhary KS et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86: 736-41
24. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11 (Pubitemid 30151999)
25. Fujita H, Koshida K, Keller ET et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-40 (Pubitemid 35266184)
26. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93-9 (Pubitemid 38174945)
27. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancers. Annu Rev Med 2002; 53: 223-43 (Pubitemid 34177880)
28. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001; 84: 1188-92 (Pubitemid 32511336)
29. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56 (Pubitemid 36055338)
30. Bensen WG, Fiechtner JJ, McMillen JI et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-105 (Pubitemid 30243242)
31. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431-6 (Pubitemid 38050040)
32. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171 (2 Pt 2): S59-62; discussion S62-3
33. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999; 128: 1121-32
34. Meric JB, Rottey S, Olaussen K et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006; 59: 51-64 (Pubitemid 43903278)
35. Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001; 59: 493-500
36. Howe LR, Subbaramaiah K, Patel J et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62: 5405-7
37. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism (s). Clin Cancer Res 2003; 9: 3503-13 (Pubitemid 37082750)
38. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-3 (Pubitemid 30225166)
39. Hernandez J, Basler JW, Thompson IM. The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. Urol Clin North Am 2004; 31: 213-8 (Pubitemid 38581219)
40. Srinath P, Rao PN, Knaus EE, Suresh MR. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res 2003; 23 (5A): 3923-8 (Pubitemid 37474344)
41. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27
42. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007; 3: 328-34 (Pubitemid 46953958)
43. Manzano A, Perez-Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? Scientific World Journal 2012; 2012: 327-41
44. Reddy BS, Hirose Y, Lubet R et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-7 (Pubitemid 30070754)
45. Sooriakumaran P, Coley HM, Fox SB et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009; 29: 1483-8
46. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723-8 (Pubitemid 46630568)
47. Antonarakis ES, Heath EI, Walczak JR et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009; 27: 4986-93
48. James ND, Sydes MR, Mason MD et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012; 13: 549-58
49. Llaurado M, Abal M, Castellvi J et al. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer 2011; 130: 1532-43
50. Tarragona M, Pavlovic M, Arnal-Estapé A et al. Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem 2012; 287: 21346-55
51. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49 (Pubitemid 36808649)
52. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-24 (Pubitemid 41112921)
53. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 1993; 53: 4890-5 (Pubitemid 23326183)
54. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 2005; 22: 674-84 (Pubitemid 44259528)
55. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-5
56. Beaver CM. The effect of culture conditions on colony morphology and proliferative capacity in human prostate cancer cell lines. Cell Biol Toxicol 2012; 28: 291-301
57. Ma Y, Liang D, Liu J et al. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol 2012; 33: 967-78
58. Ma Y, Liang D, Liu J et al. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 2011; 6: e 29170
59. Varisli L, Gonen-Korkmaz C, Syed HM et al. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells. Mol Cell Endocrinol 2012; 350: 107-17
60. Huang CH, Guh JH, Chen GS, Lu PH, Chern JW. Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 159-69
61. Zhang K, Waxman DJ. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer 2010; 9: 319-32
62. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intra-epithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10: 7727-37 (Pubitemid 39557538)
63. Kamijo T, Sato T, Nagatomi Y, Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 2001; 8: S35-9 (Pubitemid 34225135)
64. Zheng X, Cui XX, Avila GE et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007; 13 (18 Pt 1): 5480-7 (Pubitemid 47510376)
65. Adhami VM, Malik A, Zaman N et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007; 13: 1611-9 (Pubitemid 46450454)
66. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72 (Pubitemid 32927924)
67. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403 (Pubitemid 30212792)
68. James ND, Sydes MR, Clarke NW et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - a multi-arm multi-stage randomised controlled trial.Clin Oncol (R Coll Radiol) 2008; 20: 577-81
69. Patel MI, Subbaramaiah K, Du B et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999-2007 (Pubitemid 40471866)
70. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23 (Pubitemid 9239413)
71. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 2009; 602: 8-14
72. Kawashima M, Fujikawa Y, Itonaga I, Takita C, Tsumura H. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod Rheumatol 2009; 19: 192-8
73. Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 2006; 131: 267-75
74. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12 (20 Pt 2): 6296s-300s
75. Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 2012; 5: 35-43
76. Niu G, Liao Z, Cai L, Wei R, Sun L. The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. Cancer Biother Radiopharm 2008; 23: 469-76
77. Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66: 257-65 (Pubitemid 43191225)
78. Lee ME, Kim SR, Lee S et al. Cyclooxygenase-2 inhibitors modulate skin aging in a catalytic activity-independent manner. Exp Mol Med 2009; 44: 536-44
79. Kim SR, Park JH, Lee ME, Park JS, Park SC, Han JA. Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner.Mech Ageing Dev 2008; 129: 706-13
80. Xiao Y, Teng Y, Zhang R, Luo L. Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo. Oncol Lett 2012; 4: 1219-24
81. Li W, Zhai L, Tang Y, Cai J, Liu M, Zhang J. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo. Oncol Res 2012; 20: 49-59
82. Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neurooncol 2012; 106: 99-109
83. Sargeant AM, Klein RD, Rengel RC et al. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 2007; 35: 549-61 (Pubitemid 46911889)
84. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164 (3 Pt 1): 820-5 (Pubitemid 30637640)
85. Song X, Lin HP, Johnson AJ et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002; 94: 585-91 (Pubitemid 34498645)
86. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-22 (Pubitemid 38971638)
87. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 2006; 66: 6638-48 (Pubitemid 44085620)
88. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31 (2 Suppl. 7): 2-11 (Pubitemid 38879409)
89. Sales KJ, Katz AA, Davis M et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001; 86: 2243-9 (Pubitemid 32472947)
90. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004; 101: 415-6 (Pubitemid 38084650)
91. Albouy B, Tourani JM, Allain P et al. Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. BJU Int 2007; 100: 770-4 (Pubitemid 47360191)
92. Carles J, Font A, Mellado B et al. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer 2007; 97: 1206-10 (Pubitemid 350035818)
93. James ND, Sydes MR, Clarke NW et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009; 103: 464-9
94. Armstrong AJ. The STAMPEDE trial and celecoxib: how to adapt? Lancet Oncol 2012; 13: 443-5
95. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008; 122: 2115-24 (Pubitemid 351441204)
96. Zheng X, Cui XX, Gao Z et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 2010; 3: 114-24
97. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008; 59 (Suppl. 2): 117-33
98. Solomon SD, Pfeffer MA, McMurray JJ et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028-35 (Pubitemid 44358879)
99. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332-41
100. Sooriakumaran P, Kaba R. The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review. Int J Surg 2005; 3: 278-85 (Pubitemid 43129688)